22589-35-1

Basic information

• Product Name: 4-(Thiomorpholin-4-yl)aniline
• Synonyms: 4-THIOMORPHOLIN-4-YLANILINE;4-(THIOMORPHOLIN-4-YL)PHENYLAMINE;4-thiomorpholinobenzenamine;BenzenaMine, 4-(4-thioMorpholinyl)-;4-(4-ThioMorpholinyl)aniline, 97%
• CAS NO: 22589-35-1
• Molecular Formula: C₁₀H₁₄N₂S
• Molecular Weight: 194.3
• Mol File: 22589-35-1.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 399.025 °C at 760 mmHg
• Flash Point: 195.123 °C
• Appearance: /Solid
• Density: 1.189 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.64
• PKA: 7.57±0.10(Predicted)
• CAS DataBase Reference: 4-(Thiomorpholin-4-yl)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Thiomorpholin-4-yl)aniline(22589-35-1)
• EPA Substance Registry System: 4-(Thiomorpholin-4-yl)aniline(22589-35-1)

Safety Data

• HazardClass: 6.1
• Hazardous Substances Data: 22589-35-1(Hazardous Substances Data)

Usage

General Description

4-(Thiomorpholin-4-yl)aniline is a compound with the molecular formula C11H16N2S. It is a thiomorpholine derivative with an aniline group. This chemical is used in organic synthesis and medicinal chemistry as a building block for the production of various pharmaceutical and agrochemical compounds. It has been studied for its potential pharmacological activity, including its antimicrobial and antitumor properties. Its structure contains a thiomorpholine ring, which can contribute to its biological activity and chemical reactivity. Further research on this compound may reveal its potential applications in the development of new drugs and materials.

InChI:InChI=1/C10H14N2S/c11-9-1-3-10(4-2-9)12-5-7-13-8-6-12/h1-4H,5-8,11H2

Upstream product

• 90254-22-1 4-(p-nitrophenyl)-tetrahydro-4H-1,4-thiazine 
• 350-46-9 4-Fluoronitrobenzene 
• 100-00-5 4-chlorobenzonitrile 

Downstream Products

• 55330-74-0 4-(tetrahydro-4H-1,4-thiazin-4-yl)phenol 
• 1403817-48-0 N-(4-thiomorpholinophenyl)-5-(thiophen-3-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 
• 1403817-39-9 N-(4-thiomorpholinophenyl)-5-(thiophen-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 
• 1403817-71-9 5-(4-methoxyphenyl)-N-(4-thiomorpholinophenyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 
• 1403885-98-2 (8-methoxy-3H-pyrazolo[3,4-c]quinolin-4-yl)-(4-thiomorpholin-4-yl-phenyl)-amine 
• 442548-63-2 6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-thiomorpholin-4-yl-phenyl)-amide 
• 442548-40-5 8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-thiomorpholin-4-yl-phenyl)-amide 
• 487041-33-8 C₁₇H₂₆N₂O₃S 

Relevant articles and documents

Design, synthesis and biological evaluation of novel 7-amino-[1,2,4]triazolo[4,3-f]pteridinone, and 7-aminotetrazolo[1,5-f]pteridinone derivative as potent antitumor agents

To develop novel therapeutic agents with anticancer activities, two series of novel 7-amino-[1,2,4]triazolo[4,3-f]pteridinone, and 7-aminotetrazolo[1,5-f]pteridinone derivatives were designed and synthesized. All compounds were tested for anti-proliferative activities against five cancer cell lines. The structure-activity relationships (SARs) studies were conducted through the variation in two regions, the moiety of A ring and the terminal aniline B on pteridinone core. 1-Methyl-1,2,4-triazole derivative L7 with 2,6-dimethylpiperazine showed the most potent antiproliferative activity against A549, PC-3, HCT116, MCF-7 and MDA-MB-231 cell lines with IC50 values of 0.16 μM, 0.30 μM, 0.51 μM, 0.30 μM, and 0.70 μM, respectively. Combined with the results of the molecular docking and enzymatic studies, the PLK1 was very likely to be one of the drug targets of compound L7. Furthermore, to clarify the anticancer mechanism of compound L7, further explorations in the bioactivity were conducted. The results showed that compound L7 obviously inhibited proliferation of A549 cell lines, induced a great decrease in mitochondrial membrane potential leading to apoptosis of cancer cells, suppressed the migration of tumor cells, and arrested G1 phase of A549 cells.

Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3

Hybridization strategy is an effective strategy to obtain multi-target inhibitors in drug design. In this study, we assembled the pharmacophores of momelotinib and tandutinib to get a series of 4-piperazinyl-2-aminopyrimidine derivatives. All compounds were tested for the inhibition of JAK2 and FLT3 enzymes, of which, compounds with potent enzyme activities were assayed for antiproliferative activities against three cancer cell lines (HEL, MV4-11, and HL60). The structure-activity relationship studies were conducted through variations in two regions, the “A” phenyl ring and “B” phenyl ring. Compound 14j showed the most balanced in vitro inhibitory activity against JAK2 and FLT3 (JAK2 IC50 = 27 nM, FLT3 IC50 = 30 nM), and it also showed potent inhibition against the above tested cell lines. In the cellular context, 14j strongly induced apoptosis by arresting cell cycle in the G1/S phase, and was selected as a promising JAK2/FLT3 dual inhibitor.

ANTIFUNGAL AGENTS

Compounds of formula (I), and pharmaceutically acceptable salts thereof, may be used in therapy, for example as antifungal agents: (I) wherein: Rl, R2, R3, R4, R5, R6, R7, X and X1 are as defined herein. Certain compounds of formula (I) are also provided. Compounds of formula (T), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.